Icon Bioscience - Company & Market Research Reports

Icon Bioscience was founded in 2004, the headquarters are in Sunnyvale, California. This company focuses on using the verisome technology to approved or in market ophthalmic agents. They improve existing eye disease treatments. Icon’s leading product ‘Dexycu’ has completed phase III and an NDA is planned for 2017. It is used to reduce inflammation from cataract surgery. They target many diseases such as: ophthalmic indications, including glaucoma, macular edema, inflammation/infection associated with cataract surgery, and age-related macular degeneration.

From
From
From
Uveitis - Pipeline Review, H1 2018 - Product Thumbnail Image

Uveitis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 195 Pages
From
From
From
Glaucoma - Pipeline Review, H1 2018 - Product Thumbnail Image

Glaucoma - Pipeline Review, H1 2018

  • Drug Pipelines
  • 299 Pages
From
From
From
From
From
From
  • 14 Results (Page 1 of 1)
Loading Indicator
adroll